Replies to post #4034 on The Valens Company Inc. (VLNS)

[FUNMAN]

Great News (see Blue)--->>>The Valens Company Begins Manufacturing Cannabis-Infused Beverages at Greater Toronto Area Facility & Signs Manufacturing Partnership

By Q2, the cannabis infused beverages should be contributing quarterly revenue bumps of about 10% each Q based on initially penetrating the new markets, developing brand loyalty, and the size of the overall Canadian Beverage market.

Something not to be overlooked is if cannabis legalization comes to the USA, Toronto's access to the USA market via Buffalo is just 100 miles away. - FUNMAN 

The first shipment of beverages has shipped to Ontario and purchase orders for British Columbia, Alberta Manitoba, and Yukon are expected to be fulfilled in the coming days

Kelowna, B.C., February 10, 2022 – The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS)) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, today announced the successful commissioning and completion of first shipments from Pommies (otherwise known as Southern Cliff Brands) located in the Greater Toronto Area (the “GTA Facility”). The 30,000 square feet GTA Facility received a micro-processing license from Health Canada in November 2021 to begin production and manufacturing of cannabis-infused beverages.

The first shipment was shipped to Ontario on January 28, 2022, and purchase orders for British Columbia, Alberta Manitoba, and Yukon are expected to be fulfilled in the coming days.

“The GTA Facility is highly automated and built to fulfill today’s volumes while significantly bolstering our strategic potential by providing us with the operational footprint and expertise to make Valens the go-to name in cannabis-infused beverages in Canada." said Tyler Robson, Chief Executive Officer and Chairman of The Valens Company. "We are expanding our branded beverage offering with the introduction of new exciting flavours which will be coming to market over the next few quarters as well as expanding relationships with new B2B partnerships to further fill capacity.”

The GTA Facility has the capacity to manufacture more than 8 million units per year of cannabis-infused beverages in a single shift in both resealable cans and PET bottles across various sizes and formats. Products developed and manufactured in the GTA Facility will utilize Valens’ powered by SoRSE™ emulsion technology, resulting in consumer products that are free of cannabis taste and aroma and have predictable onset and offset timing. The Valens R&D team has been active in formulating a number of new products that will soon to be available in the Canadian market and is excited to introduce its innovative pipeline.

As beverages become mainstream in the ready-to-drink product category, Valens continues to build on its industry-leading market share in the category with the addition of exciting new offerings from:

A1 Beverage (355 ml bottles):
10mg Summit THC Raspberry Lemonade
10mg Summit THC Peach Lemonade

Versus (355 ml cans):
10mg THC Black Cherry Seltzer
10mg THC Lime Seltzer
10mg THC Grapefruit Seltzer
10mg THC Mango Seltzer

The Valens Company is pleased to announce it has entered into its first beverage manufacturing agreement after launch of the Pommies facility in an expanded relationship with an existing producer to produce a customized line of beverages for the Canadian market

Robson noted “Valens has worked in close collaboration with cannabis enthusiasts to bring a selection of fresh new beverages made with natural flavours in a ready-to-drink format that appeal to connoisseurs as well as first time consumers”.

At Valens, it’s Personal.

About The Valens Company

The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.

For further information, please contact:

Jeff Fallows
The Valens Company
Investor Relations
[e-mail]
1.647.956.8254

KCSA Strategic Communications
Phil Carlson
[e-mail]
1.212.896.1233

Media
KCSA Strategic Communications
Anne Donohoe
[e-mail]
1 212.896.1265

Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.

The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

[FUNMAN]

McConnell already called this out and basically said over my dead body when the bill showed up last week.

But if it happens, it's a big step in the right direction for Valens.

Believe it when it happens. Perlmutter"s strategy is to make it a poison pill for republicans. --->>> House Marijuana Banking Bill Sponsor Is ‘Confident’ It Will Advance Through Senate Despite Obstacles

Watch the video here:

“Eight years of my 16 year career I’ve been working on this, since Colorado legalized marijuana back in 2012-2013,” @RepPerlmutter says about the Safe Banking Act. “I am confident that the Senate will take it up.” More: pic.twitter.com/CCeRHzFgcm

— Yahoo Finance (@YahooFinance) February 11, 2022

Published 3 days ago on February 11, 2022By Kyle Jaeger

https://www.marijuanamoment.net/house-marijuana-banking-bill-sponsor-is-confident-it-will-advance-through-senate-despite-obstacles/


The fight continues to get the Senate to pass a marijuana banking reform bill, and the measure’s House sponsor says he’s “confident” that the opposite chamber will finally take it up.

Rep. Ed Perlmutter (D-CO) has been trying to get the Secure and Fair Enforcement (SAFE) Banking Act across the finish line for several years now, and his latest attempt is to pass it as part of a large-scale manufacturing and innovation bill to which the cannabis language was recently attached in the House.

In an interview with Yahoo Finance on Friday, the congressman discussed the prospects of his proposal, which has cleared the House six times in some form now. He said that while Senate leadership has insisted on passing comprehensive legalization first, he still sees opportunities to advance his bipartisan incremental reform.

“Every [House] Democrat and at least half the Republicans have supported SAFE Banking, and I am confident that the Senate will take it up,” he said. He recognized that Senate Majority Leader Chuck Schumer (D-NY) and colleagues are prioritizing broad legalization legislation that they plan to formally file in April, but he said that he’s “questioned whether they have the votes to get something of that magnitude through the Senate, which has not even had a hearing really on marijuana in 50 plus years.”

“We’re going to keep working with the Senate, working with Schumer’s office, working with [Sen. Cory Booker’s (D-NJ)] office working with [Sen. Steve Daines (R-MT)], a Republican who is championing this bill in the Senate, and we’re going to get it across the finish line,” Perlmutter said. “I am really pretty confident about it, whether it’s with the [the America COMPETES Act] or something else, we’re going to get it done.”

The congressman, who is retiring at the end of the session and has committed himself to getting SAFE Banking enacted before then, also talked about the political dynamics that have prevented his reform bill from moving through the Senate.

Under prior GOP control, it stalled because a key Republican committee chairman felt it was too broad, he said. Under Democratic control, it’s yet to advance because leadership feels it’s too narrow.

He reiterated that he would be open to further amending the proposal to satisfy Schumer and his colleagues.

“They’re in support of it, but they just want to try to get some bigger pieces to it,” he said. “If they can add research, if they can add some criminal justice reform, if they can add some taxation components, I’m all for it. But we need to get something passed and on to the president this year.”

He made similar comments in response to a question from Marijuana Moment during a press briefing last week, when he also discussed possible consequences of expanding the reform proposal too much to the point where it loses some critical Republican support.

“Really, I’m pretty confident that it’s going to happen,” he said in the new interview. “I think this is the bill that’s going to break the ice, and then other things can be added or advocated for over the course of the next few months or years.”

Meanwhile, some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House, too. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue in December.

In the interim, federal financial regulator Rodney Hood—a board member and former chairman of the federal National Credit Union Administration (NCUA)—recently said that marijuana legalization is not a question of “if” but “when,” and he’s again offering advice on how to navigate the federal-state conflict that has left many banks reluctant to work with cannabis businesses.

[FUNMAN]

The Valens Company to Hold Conference Call to Discuss Financial Results for the Fourth Quarter and Fiscal Year 2021

Kelowna, B.C., February 17, 2022 – The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the “Company” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, is pleased to announce it will issue its fourth quarter and fiscal year 2021 financial results for the period ended November 30, 2021, on Monday, February 28, 2022, after market close.

CONFERENCE CALL DETAILS

The Company will host a conference call the following day, Tuesday, March 1, 2022 at 11:00 am Eastern Time / 8:00 am Pacific Time to discuss the financial results and business outlook.

Participant Dial-In Numbers:

Toll-Free: 1-877-407-0792
Toll / International: 1-201-689-8263
*Participants should request The Valens Company Earnings Call or provide confirmation code 13727202.

The call will be available via webcast on the Valens investor page of the Company website at https://thevalenscompany.com/investors/ or at this link. Please visit the website at least 15 minutes prior to the call to register, download, and install any necessary audio software. A replay of the call will be available on the Valens investor page approximately two hours after the conference call has ended.

Tyler Robson, Chief Executive Officer, Sunil Gandhi, Chief Financial Officer, Jeffrey Fallows, President, and Everett Knight, Executive Vice President of Corporate Development and Capital Markets, will be conducting a question-and-answer session following the prepared remarks.

About The Valens Company

The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company at http://www.thevalenscompany.com.

For further information, please contact:

Jeff Fallows
The Valens Company
Investor Relations
[e-mail]
1.647.956.8254

KCSA Strategic Communications
Phil Carlson
[e-mail]
1.212.896.1233

Media
KCSA Strategic Communications
Anne Donohoe
[e-mail]
1 212.896.1265

Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.

The risks and uncertainties that may affect forward-looking statements include, among others, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.